DOCSLIB.ORG

ANALYSIS of ALTERNATIVES and SOCIO-ECONOMIC ANALYSIS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANALYSIS of ALTERNATIVES and SOCIO-ECONOMIC ANALYSIS ANALYSIS OF ALTERNATIVES and SOCIO-ECONOMIC ANALYSIS PUBLIC VERSION Legal name of applicant(s): BASF SE Submitted by: BASF SE Substance: 1,2-dichloroethane (EDC) (EC Number: 203-458-1, CAS Number: 107-06-2) Use title: Industrial use as a recyclable solvent and extraction agent in a closed system for purification of 1,3,5-trioxane Use number: 1 ANALYSIS OF ALTERNATIVES and SOCIO-ECONOMIC ANALYSIS CONTENTS DECLARATION .................................................................................................................................................... 5 1. SUMMARY .................................................................................................................................................. 6 2. AIMS AND SCOPE OF THE ANALYSIS .................................................................................................. 8 2.1 Aim of the AoA and SEA ............................................................................................................................ 8 2.2 Substitution strategy .................................................................................................................................... 8 2.3 Boundaries of the AoA and SEA ................................................................................................................. 8 2.4 Relevant supply chains ................................................................................................................................ 8 3. APPLIED FOR “USE” SCENARIO ............................................................................................................. 9 3.1 Analysis of substance function .................................................................................................................... 9 3.1.1 Details of the function performed ......................................................................................................... 9 3.1.2 Process conditions ............................................................................................................................ 10 3.1.3 Functional requirements ................................................................................................................... 10 3.2 Market and business trends including the use of the substance ................................................................. 11 3.2.1 Annual tonnage of EDC ..................................................................................................................... 11 3.2.2 Market trends for trioxane and POM ................................................................................................. 11 3.3 Remaining risk of the “applied for use” scenario ...................................................................................... 12 3.3.1 Overview ........................................................................................................................................... 12 3.3.2 Risks to workers of the applied for use .............................................................................................. 13 3.3.3 Risks for humans exposed via the environment ................................................................................. 14 3.4 Human health and environmental impacts of the applied for use scenario ................................................ 14 3.5 Monetised damage of human health and environmental impacts .............................................................. 15 4. SELECTION OF THE “NON-USE” SCENARIO ..................................................................................... 17 4.1 Efforts made to identify alternatives .......................................................................................................... 17 4.1.1 Research and development ................................................................................................................. 17 4.1.2 Data searches ..................................................................................................................................... 18 4.2 Identification of known alternatives .......................................................................................................... 19 4.3 Assessment of shortlisted alternatives ....................................................................................................... 20 4.3.1 Alternative 1 – Benzene ...................................................................................................................... 20 4.3.2 Alternative 2 – Dichloromethane (DCM) ........................................................................................... 21 4.3.3 Alternative 3 – N-butyl methyl ether .................................................................................................. 23 4.3.4 Alternative 4 – Isoflurane ................................................................................................................... 25 4.3.5 Alternative 5 – Crystallisation (alternative technology) .................................................................... 26 4.3.6 Alternative 6 – Pressure swing distillation (alternative technology) ................................................. 28 4.4 The most likely non-use scenario ............................................................................................................... 30 4.4.1 Summary of conclusions on alternatives ............................................................................................ 30 4.4.2 Implications of switching to an alternative ........................................................................................ 31 4.4.4 Overall conclusions on the non-use scenario ..................................................................................... 33 5. IMPACTS OF GRANTING AUTHORISATION ...................................................................................... 34 5.1 Economic impacts ...................................................................................................................................... 34 5.1.1 Scope of the analysis .......................................................................................................................... 34 5.1.2 Supply/value chain and markets affected ........................................................................................... 34 5.1.3 Direct economic impacts for BASF .................................................................................................... 35 5.1.4 Economic impacts for downstream users (POM processors)............................................................. 36 5.1.5 Economic impacts for end-users ........................................................................................................ 37 5.1.6 Significance of impacts and uncertainties .......................................................................................... 39 5.2 Human health and environmental impacts ................................................................................................. 40 5.3 Social impacts ............................................................................................................................................ 40 5.4 Wider economic impacts ............................................................................................................................ 41 5.5 Distributional impacts ................................................................................................................................ 41 Public Version 2 ANALYSIS OF ALTERNATIVES and SOCIO-ECONOMIC ANALYSIS 5.6 Uncertainty analysis ................................................................................................................................... 41 6. CONCLUSIONS ......................................................................................................................................... 43 6.1 Comparison of the benefits and risk .......................................................................................................... 43 6.2 Information for the length of the review period ......................................................................................... 45 6.3 Substitution effort taken by the applicant if an authorisation is granted .................................................... 47 7. REFERENCES ........................................................................................................................................... 48 Annex – Justifications for Confidentiality Claims ................................................................................................ 49 APPENDCES ....................................................................................................................................................... 50 Appendix 1: ..................................................................................................................................................... 51 Appendix 2: ..................................................................................................................................................... 52 Appendix 3: ..................................................................................................................................................... 53 TABLES List of tables Table 1 Sales volume, value and profitability of Ultraform® plant .................................................................... 12 Table 2 ECHA estimates of benefits of avoiding cancer ....................................................................................
Load more

Recommended publications
  • Isovaline Monohydrate
    organic compounds Acta Crystallographica Section E Structure Reports Online ISSN 1600-5368 Isovaline monohydrate Ray J. Butcher,a* Greg Brewer,b Aaron S. Burtonc and Experimental d Jason P. Dworkin Crystal data ˚ 3 C5H11NO2ÁH2O V = 736.10 (12) A aDepartment of Chemistry, Howard University, 525 College Street NW, Washington, Mr = 135.16 Z =4 DC 20059, USA, bDepartment of Chemistry, Catholic University of America, Orthorhombic, P212121 Cu K radiation Washington, DC 20064, USA, cNASA Johnson Space Center, Astromaterial and a = 5.9089 (5) A˚ = 0.84 mmÀ1 Exploration Science Directorate, Houston, TX 77058, USA, and dSolar System b = 10.4444 (10) A˚ T = 123 K Exploration Division, NASA Goddard Space Flight Center, Greenbelt, MD 20771, c = 11.9274 (11) A˚ 0.48 Â 0.08 Â 0.06 mm USA Correspondence e-mail: [email protected] Data collection Agilent Xcalibur (Ruby, Gemini) 1662 measured reflections Received 23 October 2013; accepted 20 November 2013 diffractometer 1204 independent reflections Absorption correction: multi-scan 1072 reflections with I >2(I) (CrysAlis PRO; Agilent, 2012) Rint = 0.072 ˚ Key indicators: single-crystal X-ray study; T = 123 K; mean (C–C) = 0.005 A; Tmin = 0.383, Tmax = 1.000 R factor = 0.056; wR factor = 0.162; data-to-parameter ratio = 13.2. Refinement R[F 2 >2(F 2)] = 0.056 H atoms treated by a mixture of The title compound, C5H11NO2ÁH2O, is an isomer of the - wR(F 2) = 0.162 independent and constrained amino acid valine that crystallizes from water in its zwitterion S = 1.11 refinement ˚ À3 form as a monohydrate.
    [Show full text]
  • Alma Mater Studiorum –– Università Di Bologna
    Alma Mater Studiorum –– Università di Bologna DOTTORATO DI RICERCA IN Scienze Chimiche Ciclo XXIV Settore Concorsuale di afferenza: CHIM/06 Settore Scientifico disciplinare: CHIMICA ORGANICA TITOLO TESI Synthesis of Modified Amino Acids and Insertion in Peptides and Mimetics. Structural Aspects and Impact on Biological Activity. Presentata da: De Marco Rossella Coordinatore Dottorato Relatore Prof. Adriana Bigi Prof. Luca Gentilucci Esame finale anno 2012 1 Synthesis of Modified Amino Acids and Insertion in Peptides and Mimetics. Structural Aspects and Impact on Biological Activity. by Rossella De Marco 2012 2 To My Self 3 Table of Contents Cap 1. Chemical Modifications Designed to Improve Peptide Stability 1. Introduction 1.2. Enzymatic Degradation of Peptides 1.3. Structure Modifications to Improve Peptide Stability 1.3.1.Pseudopeptides 1.3.2. Reduced Peptide Bonds 1.3.3. Azapeptides 1.3.4. Retro-Inverso Peptides 1.3.5. Peptoids 1.4. Incorporation of Non-Natural Amino Acids 1.4.1. D-Amino Acids 1.4.2. N-Alkylated Amino Acids 1.4.3. α-Substituted α-Amino-Acids 1.4.4. β-Substituted α-Amino Acids 1.4.5. Proline analogues 1.4.6. β-Amino-Acids 1.5. Cyclization 1.6. β-Turn-Mimetics 1.7. Conclusion References Chapter 2. Cyclopeptide Analogs for Generating New Molecular and 3D Diversity. 2. Introduction 2. 1. Matherial and Methods 2.2. General Methods. 2.3. General Procedure for Peptide Coupling 2.3.1. Boc group deprotection 2.3.2. Fmoc group deprotection 2.3.3. Cbz and benzyl group deprotection 2.3.4. General Procedure for Peptide Cyclization 2.4.
    [Show full text]
  • Metabolism of D1-Valine and D1-Isovaline in the Normal
    Ai ABSTRACT OF ThE THESIS OF ___________ for (Naine) (Degree) (Majer) Date Thesis presented__._-J-9LJ-____ THE T i tie - - 9 .PY. NO.MAL RAT- Abstract Approved: (kiajor Professor) Up to the present time no in±ormation is available as to the role of di-valine in metabolism except that it is an ind.ispensllJle amino acid. and must be su.pplied in the diet of' the animal if' growth and. life is to contlnu.e. Experimental techniques that lately have been applied. to the stu.ay of other amino acids might yield sorne inform- ation in this problem and assign to di-valine a definite role as a glycogenic or as a ketone-prod.u.cing compound. The ketolytic properties of di-valine have beem dem- onstrated by the decrease in level of acetonuria of' fasting rats fed di-valine when the ketonaria arises from endogen- oua stores. These ketolrt1c results have been further substantiated when fasting rats were fed. sodium butyrate to heighten the already existing acetonu.ria. This ketolytic effect should derive its origin from the formation of' liver glycogen. Liver glycogen studies were carried. out to test this hypothesis. Small but sign- ificant amounts of glycogen were founa after feeding dl- valine. Thus, affording further proof' that di-valine may be considered a weakly glycogenic amino acid. No glycogen was found after feeding di-isovaline. Absorption studies were made and the rates of absorp- tion of di-valine and di-isovaline were found to confirm to the values previously reported by Chase and Lewis.
    [Show full text]
  • Publikationsliste Prof. Dr. D. Seebach
    Publikationsliste Prof. Dr. D. Seebach 1 + Diplomarbeit: Dieter Seebach Zur Reaktion von Bleitetraacetat mit 1,1-Diphenyl-2-hydroperoxy-propiomesitylen Technische Hochschule Karlsruhe, 1961 2 + Dissertation: Dieter Seebach 2.5-Dihydro-Furan-Peroxyde Technische Hochschule Karlsruhe, 1964 3 Rudolf Criegee, Dieter Seebach Ein Bishydroperoxyd mit ungewöhlicher Bildungstendenz Chem. Ber. 96, 2704 - 2711 (1963) 4 Dieter Seebach Die Reaktion von 2.5-Dimethyl-furan mit Wasserstoffperoxyd Chem. Ber. 96, 2712 - 2722 (1963) 5 Dieter Seebach Die Reaktion von Pentamethylpyrrol mit Wasserstoffperoxyd Chem. Ber. 96, 2723 - 2729 (1963) 6 Rudolf Criegee, Ulrich Zirngibl, Harald Furrer, Dieter Seebach, Günther Freund Photosynthese substituierter Cyclobutene Chem. Ber. 97, 2942 - 2948 (1964) 7 Dieter Seebach Über ein sehr labiles Bicyclo(2.2.0)hexen-Derivat Chem. Ber. 97, 2953 - 2958 (1964) 8 * Dieter Seebach Gespannte polycyclische Systeme aus Drei-und Vierring-Bausteinen Angew. Chem. 77, 119 - 129 (1965) Angew. Chem. Int. Ed. Engl. 4, 121 - 131 (1965) 9 Rudolf Criegee, Haukur Kristinsson, Dieter Seebach, Fritz Zanker Eine neuartige Synthese von Bicyclo(2.2.0)hexen-(2)-Derivaten Chem. Ber. 98, 2331 - 2338 (1965) 10 Rudolf Criegee, Dieter Seebach, Rudolf Ernst Winter, Bernt Börretzen, Hans-Albert Brune Valenzisomerisierungen von Cyclobutenen Chem. Ber. 98, 2339 - 2352 (1965) 11 Elias J. Corey, Dieter Seebach Carbanionen der 1,3-Dithiane, Reagentien zur C-C-Verknüpfung durch nucleophile Substitution oder Carbonyl-Addition Angew. Chem. 77, 1134 - 1135 (1965) Angew. Chem. Int. Ed. Engl. 4, 1075 - 1077 (1965) 12 Elias J. Corey, Dieter Seebach Synthese von 1,n-Dicarbonylverbindungen mit Carbanionen der 1,3-Dithiane Angew. Chem. 77, 1135 - 1136 (1965) Angew.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,524,835 B2 Frincke (45) Date of Patent: Apr
    USOO7524835B2 (12) United States Patent (10) Patent No.: US 7,524,835 B2 Frincke (45) Date of Patent: Apr. 28, 2009 (54) TETROL STEROIDS AND ESTERS 5,912,240 A 6/1999 Loria 5,919,465. A 7/1999 Daynes et al. (75) Inventor: James M. Frincke, San Diego, CA (US) 5,922,701 A 7/1999 Araneo (73) Assignee: Hollis-Eden Pharmaceuticals, Inc., San 5,929,060 A 7/1999 Araneo Diego, CA (US) 6,111,118 A 8, 2000 Marwah et al. 6,150,348 A 11/2000 Araneo et al. (*) Notice: Subject to any disclaimer, the term of this 6,187,767 B1 2/2001 Araneo et al. patent is extended or adjusted under 35 6,384,251 B1 5, 2002 Marwah et al. U.S.C. 154(b) by 272 days. 6,476,011 B1 1 1/2002 Reed et al. (21) Appl. No.: 10/607,415 6,667,299 B1 12/2003 Ahlem et al. 6,686,486 B1 2/2004 Marwah et al. (22) Filed: Jun. 25, 2003 6,949,561 B1 9, 2005 Reed et al. 65 Prior Publication D 2003/0232797 Al 12/2003 Kutney et al. (65) rior Publication Data 2004/0019026 A1 1/2004 Schwartz et al. US 2006/OO63749 A1 Mar. 23, 2006 2004/0162425 A1 8/2004 Burgoyne et al. Related U.S. Application Data (63) Continuation of application No. 09/535,675, filed on Mar. 23, 2000, now Pat. No. 6,667,299, which is a FOREIGN PATENT DOCUMENTS continuation-in-part of application No. 09/414.905, filed on Oct.
    [Show full text]
  • Part 7. Indexes
    Peptide Sequences Index Part 7. Indexes Index A. Peptide Sequences White & White - Proteins, Peptides & Amino Acids SourceBook 975 Peptide Sequences Index Ala-Ala-Pro-Lys . 218 A Ala-Ala-Pro-Met . 218 Ala-Ala-Pro-Nle . 218 Abu-Ala· 208 Ala-Ala-Pro-Nva . 218 Abu-Arg . 208, 740 Ala-Ala-Pro-Orn • 218 Abu-Asn-Arg-Leu-Glu-Ala-Ser-Ser-Arg-Ser-Ser-Lys . 208 Ala-Ala-Pro-Phe . 209, 218, 219, 385 Abu-Gly . 208, 369 Ala-Ala-Pro-Val . 217, 219, 220 Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr· 208 Ala-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr . 220 Abu-Ser-Gln-Asn-Tyr-Pro-lie-Val-Gin· 208 Ala-Ala-Trp-Phe-Lys· 220 Abz-Ala-Ala-Phe-Phe . 208 Ala-Ala-Trp-Phe-Pro-pro-Nle . 220 Abz-Ala-Arg-Val-Nle-Phe-Glu-Ala-Nle . 208 Ala-Ala-Tyr . 221 Abz-Ala-Gly-Leu-Ala . 208 Ala-Ala-Tyr-Ala . 221 Abz-Ala-Phe-Ala-Phe-Asp-Val-Phe-Tyr-Asp . 209 Ala-Ala-Tyr-Ala-Ala . 221 Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr-Asp . 209 Ala-Ala-Val· 221, 222 Abz-Arg-Val-Nle-Phe-Glu-Ala-Nle . 209 Ala-Ala-Val-Ala • 221, 222 Abz-Gln-Val-Val-Ala-Gly-Ala . 209 Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu- Abz-Glu-Thr-Leu-Phe-Gln-Gly-Pro-Val-Phe . 209 Ala-Pro-Asp-Glu-Val-Asp . 221 Abz-Gly . 209, 385 Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu­ Abz-Gly-Ala-Ala-Pro-Phe-Tyr-Asp .
    [Show full text]
  • Systemic and Intrathecal Baclofen Produce Bladder Antinociception in Rats
    Systemic and Intrathecal Baclofen Produce Bladder Antinociception in Rats Timothy J. Ness ( [email protected] ) University of Alabama at Birmingham Alan Randich University of Alabama at Birmingham Xin Su Medtronic (United States) Cary DeWitte University of Alabama at Birmingham Keith Hildebrand Medtronic (United States) Research Article Keywords: interstitial cystitis/bladder pain syndrome, antinociception, urinary bladder, GABAB receptors Posted Date: May 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-443067/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/24 Abstract Background Baclofen, a clinically available GABAB receptor agonist, produces non-opioid analgesia in multiple models of pain but has not been tested for effects on bladder nociception. Methods A series of experiments examined the effects of systemic and spinally administered baclofen on bladder nociception in female anesthetized rats. Models of bladder nociception included those which employed neonatal and adult bladder inammation to produce bladder hypersensitivity. Results Cumulative intraperitoneal dosing (1–8 mg/kg IP) and cumulative intrathecal dosing (10–160 ng IT) of baclofen led to dose-dependent inhibition of visceromotor responses (VMRs) to urinary bladder distension (UBD) in all tested models. There were no differences in the magnitude of the analgesic effects of baclofen as a function of inammation versus no inammation treatments. Hemodynamic (pressor) responses to UBD were similarly inhibited by IT baclofen as well as UBD-evoked excitatory responses of spinal dorsal horn neurons. The GABAB receptor antagonist, CGP 35348, antagonized the antinociceptive effects of IT baclofen on VMRs in all tested models but did not affect the magnitude of the VMRs by itself suggesting no tonic GABAB activity was present in this preparation.
    [Show full text]
  • Template for Electronic Submission to ACS Journals
    Stereoselective Biocatalysis. A mature technology for the asymmetric synthesis of pharmaceutical building blocks Jesús Albarrán-Velo, Daniel González-Martínez and Vicente Gotor-Fernández* a Organic and Inorganic Chemistry Department, Biotechnology Institute of Asturias (IUBA), University of Oviedo, Avenida Julián Clavería s/n, 33006 Oviedo, Spain. Corresponding author: [email protected] Phone: +34 98 5103454. Fax: +34 98 5103446 Dedicated to Professor Vicente Gotor on occasion of his 70th birthday Keywords: Biocascades; Biotransformations; Hydrolases; Natural products; Oxidoreductases; Pharmaceuticals. Abstract Biocatalysis is gaining increasing attention in the academic and industrial sector due to the possibility of developing highly stereoselective transformations in a sustainable manner. The creation of stereogenic centers in organic synthesis is not trivial and multiple approaches have been disclosed based on 1 organometallic and organocatalytic methods with the use of day by day more complex catalysts to induce asymmetry in selected transformations. The intrinsic chirality of enzymes makes them powerful tools for the development of stereoselective transformations, catalysing a wide range of chemical reactions due to the high abundance and diversity of enzymes in nature. In addition, the enormous advances in rational design and molecular biology methods have opened up the possibility to create more robust and versatile biocatalysts, which have improved the initial activities displayed by wild-type enzymes. Therefore, their applicability has been widely increased in terms of reaction conditions, substrate specificity, activity and selectivity among others. All these properties have attracted the industrial sector, which has taken advantage of the enzyme selectivities in multiple scenarios. Herein, the focus has been put in recent developments of stereoselective transformations for the synthesis of valuable building blocks towards the production of pharmaceuticals and biologically active natural products.
    [Show full text]
  • COMMISSION DECISION of 23 February 1999 Adopting a Register
    1999D0217 — EN — 03.08.2000 — 001.001 — 1 This document is meant purely as documentation tool and the institutions do not assume any liability for its contents " B COMMISSION DECISION of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC) (OJ L 84, 27.3.1999, p. 1) Amended by: Official Journal Nopage date "M1 Commission Decision 2000/489/EC of 18 July 2000 L 197 53 3.8.2000 1999D0217 — EN — 03.08.2000 — 001.001 — 2 !B COMMISSION DECISION of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 laying down a Community procedure for flavouring substances used or intended for use in or on foodstuffs (1) and in particular Article 3(2) thereof; Whereas, in application of Article 3(1) of Regulation (EC) No 2232/96, Member States, within one year of the entry into force of the abovementioned Regulation, shall notify to the Commission the list of flavouring substances accepted for
    [Show full text]
  • Dynamic Transitions in Neuronal Network Firing Sustained by Abnormal Astrocyte Feedback
    Hindawi Neural Plasticity Volume 2020, Article ID 8864246, 13 pages https://doi.org/10.1155/2020/8864246 Research Article Dynamic Transitions in Neuronal Network Firing Sustained by Abnormal Astrocyte Feedback Yangyang Yu ,1 Zhixuan Yuan ,1 Yongchen Fan ,1 Jiajia Li ,2 and Ying Wu 1 1State Key Laboratory for Strength and Vibration of Mechanical Structures, School of Aerospace Engineering, Xi’an Jiaotong University, Xi’an 710049, China 2School of Information & Control Engineering, Xi’an University of Architecture & Technology, 710055, China Correspondence should be addressed to Jiajia Li; [email protected] and Ying Wu; [email protected] Received 21 August 2020; Revised 24 October 2020; Accepted 28 October 2020; Published 23 November 2020 Academic Editor: Rubin Wang Copyright © 2020 Yangyang Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Astrocytes play a crucial role in neuronal firing activity. Their abnormal state may lead to the pathological transition of neuronal firing patterns and even induce seizures. However, there is still little evidence explaining how the astrocyte network modulates seizures caused by structural abnormalities, such as gliosis. To explore the role of gliosis of the astrocyte network in epileptic seizures, we first established a direct astrocyte feedback neuronal network model on the basis of the hippocampal CA3 neuron- astrocyte model to simulate the condition of gliosis when astrocyte processes swell and the feedback to neurons increases in an abnormal state. We analyzed the firing pattern transitions of the neuronal network when astrocyte feedback starts to change via increases in both astrocyte feedback intensity and the connection probability of astrocytes to neurons in the network.
    [Show full text]
  • A New Family of Extraterrestrial Amino Acids in the Murchison Meteorite
    www.nature.com/scientificreports OPEN A new family of extraterrestrial amino acids in the Murchison meteorite Received: 16 November 2016 Toshiki Koga1 & Hiroshi Naraoka1,2 Accepted: 8 March 2017 The occurrence of extraterrestrial organic compounds is a key for understanding prebiotic organic Published: xx xx xxxx synthesis in the universe. In particular, amino acids have been studied in carbonaceous meteorites for almost 50 years. Here we report ten new amino acids identified in the Murchison meteorite, including a new family of nine hydroxy amino acids. The discovery of mostly C3 and C4 structural isomers of hydroxy amino acids provides insight into the mechanisms of extraterrestrial synthesis of organic compounds. A complementary experiment suggests that these compounds could be produced from aldehydes and ammonia on the meteorite parent body. This study indicates that the meteoritic amino acids could be synthesized by mechanisms in addition to the Strecker reaction, which has been proposed to be the main synthetic pathway to produce amino acids. The extraterrestrial synthesis of amino acids is an intriguing discussion concerning the chemical evolution for the origins of life in the universe, because amino acids are fundamental building blocks of terrestrial life. The extrater- restrial amino acid distribution has been extensively examined using carbonaceous chondrites, which are the most chemically primitive meteorites containing volatile components such as water and organic matter, particularly the Murchison meteorite since it’s fall in 1969. The Murchison meteorite is classified as a CM2 (Mighei-type) chon- drite, moderately altered by aqueous activity on the parent body (e.g. ref. 1). Currently, a total of 86 amino acids have been identified in the Murchison meteorite as α, β, γ and δ amino structures with a carbon number between 2–4 C2 and C9 including dicarboxyl and diamino functional groups .
    [Show full text]
  • 1999D0217 — En — 20.02.2002 — 002.001 — 1
    1999D0217 — EN — 20.02.2002 — 002.001 — 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents ►B COMMISSION DECISION of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC) (OJ L 84, 27.3.1999, p. 1) Amended by: Official Journal No page date ►M1 Commission Decision 2000/489/EC of 18 July 2000 L 197 53 3.8.2000 ►M2 Commission Decision 2002/113/EC of 23 January 2002 L 49 1 20.2.2002 1999D0217 — EN — 20.02.2002 — 002.001 — 2 ▼B COMMISSION DECISION of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Regulation (EC) No 2232/96 of the European Parliament and of the Council of 28 October 1996 laying down a Community procedure for flavouring substances used or intended for use in or on foodstuffs (1) and in particular Article 3(2) thereof; Whereas, in application of Article 3(1) of Regulation (EC) No 2232/96, Member States, within one year of the entry into force of the abovementioned Regulation, shall
    [Show full text]